Compare CSTE & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSTE | FEMY |
|---|---|---|
| Founded | 1987 | 2004 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.9M | 51.5M |
| IPO Year | 2012 | 2021 |
| Metric | CSTE | FEMY |
|---|---|---|
| Price | $1.57 | $0.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $5.00 | ★ $6.83 |
| AVG Volume (30 Days) | 511.2K | ★ 1.9M |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $400,656,000.00 | $2,061,502.00 |
| Revenue This Year | N/A | $64.02 |
| Revenue Next Year | $1.59 | $147.19 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 63.53 |
| 52 Week Low | $0.86 | $0.31 |
| 52 Week High | $5.04 | $1.80 |
| Indicator | CSTE | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 55.28 | 51.24 |
| Support Level | $0.86 | $0.79 |
| Resistance Level | $1.95 | $0.91 |
| Average True Range (ATR) | 0.21 | 0.07 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 64.49 | 26.06 |
Caesarstone Ltd manufactures engineered quartz surfaces. Its products include engineered quartz and porcelain slabs, which are used as kitchen countertops in renovation and remodeling, and residential construction. It also has other applications, including vanity tops, wall panels, backsplashes, floor tiles, stairs, and other interior surfaces that are used in various residential and non-residential applications. The company sells its products under the Caesarstone brand. Caesarstone's geographical segments are the United States, Canada, Latin America, Australia, Asia, Israel, and EMEA(Europe, Middle East, Africa).
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.